相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Regression of cervical spinal cord compression in a patient with chordoma following treatment with cetuximab and gefitinib
Ola Linden et al.
ACTA ONCOLOGICA (2009)
PI3KCA/PTEN deregulation contributes to impaired responses to cetuximab in metastatic colorectal cancer patients
F. Perrone et al.
ANNALS OF ONCOLOGY (2009)
Response to imatinib plus sirolimus in advanced chordoma
S. Stacchiotti et al.
ANNALS OF ONCOLOGY (2009)
Aberrant Hyperactivation of Akt and Mammalian Target of Rapamycin Complex 1 Signaling in Sporadic Chordomas
Sangyeul Han et al.
CLINICAL CANCER RESEARCH (2009)
Response to Sunitinib Malate in Advanced Alveolar Soft Part Sarcoma
Silvia Stacchiotti et al.
CLINICAL CANCER RESEARCH (2009)
Low-scale phosphoproteome analyses identify the mTOR effector p70 S6 kinase 1 as a specific biomarker of the dual-HER1/HER2 tyrosine kinase inhibitor lapatinib (Tykerb (R)) in human breast carcinoma cells
A. Vazquez-Martin et al.
ANNALS OF ONCOLOGY (2008)
Phosphatidylinositol 3-kinase-dependent transcriptional silencing of the translational repressor 4E-BP1
R. Azar et al.
CELLULAR AND MOLECULAR LIFE SCIENCES (2008)
Rapamycin differentially inhibits S6Ks and 4E-BP1 to mediate cell-type-specific repression of mRNA translation
Andrew Y. Choo et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
Coactivation of receptor tyrosine kinases affects the response of tumor cells to targeted therapies
Jayne M. Stommel et al.
SCIENCE (2007)
4E-Binding protein 1:: A key molecular Funnel factor in human cancer with clinical implications
Gemma Armengol et al.
CANCER RESEARCH (2007)
Analysis of potential receptor tyrosine kinase targets in intimal and mural sarcomas
E. Tamborini et al.
JOURNAL OF PATHOLOGY (2007)
RAS/ERK signaling promotes site-specific ribosomal protein S6 phosphorylation via RSK and stimulates cap-dependent translation
Philippe P. Roux et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2007)
Combination of EGFR gene copy number and protein expression predicts outcome for advanced non-small-cell lung cancer patients treated with gefitinib
F. R. Hirsch et al.
ANNALS OF ONCOLOGY (2007)
Molecular and biochemical analyses of platelet-derived growth factor receptor (PDGFR) B, PDGFRA, and KIT receptors in chordomas
Elena Tamborini et al.
CLINICAL CANCER RESEARCH (2006)
Molecular and cytogenetic subgroups of oropharyngeal squamous cell carcinoma
Federica Perrone et al.
CLINICAL CANCER RESEARCH (2006)
Lapatinib: A novel EGFR/HER2 tyrosine kinase inhibitor for cancer
Stephen R. D. Johnston et al.
DRUGS OF TODAY (2006)
Ras, PI(3)K and mTOR signalling controls tumour cell growth
Reuben J. Shaw et al.
NATURE (2006)
PDGFRα, PDGFRβ and KIT expression/activation in conventional chondrosarcoma
MS Lagonigro et al.
JOURNAL OF PATHOLOGY (2006)
Effectiveness of cetuximab/gefitinib in the therapy of a sacral chordoma
Holger Hof et al.
ONKOLOGIE (2006)
Ribosomal protein S6 phosphorylation: from protein synthesis to cell size
Igor Ruvinsky et al.
TRENDS IN BIOCHEMICAL SCIENCES (2006)
Increased epidermal growth factor receptor gene copy number detected by fluorescence in situ hybridization associates with increased sensitivity to gefitinib in patients with bronchioloalveolar carcinoma subtypes: A Southwest Oncology Group Study
FR Hirsch et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Differential expression of epidermal growth factor receptor, c-Met, and HER2/neu in chordoma compared with 17 other malignancies
PM Weinberger et al.
ARCHIVES OF OTOLARYNGOLOGY-HEAD & NECK SURGERY (2005)
Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer
F Cappuzzo et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2005)
Macrophage colony-stimulating factor receptor c-fms is a novel target of imatinib
AL Dewar et al.
BLOOD (2005)
Therapeutic intervention in leukemias that express the activated fms-like tyrosine kinase 3 (FLT3): opportunities and challenges
DW Sternberg et al.
CURRENT OPINION IN HEMATOLOGY (2005)
Sacrococcygeal chordomas in patients with tuberous sclerosis complex show somatic loss of TSC1 or TSC2
L Lee-Jones et al.
GENES CHROMOSOMES & CANCER (2004)
BRAF alterations are associated with complex mutational profiles in malignant melanoma
M Daniotti et al.
ONCOGENE (2004)
Mapping of candidate region for chordoma development to 1p36.13 by LOH analysis
P Riva et al.
INTERNATIONAL JOURNAL OF CANCER (2003)
HER-2/neu assessment in primary chemotherapy treated breast carcinoma:: no evidence of gene profile changing
GP Dagrada et al.
BREAST CANCER RESEARCH AND TREATMENT (2003)
ERK and p38 inhibit the expression of 4E-BP1 repressor of translation through induction of Egr-1
M Rolli-Derkinderen et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2003)
Anti-tumor activity of GW572016: a dual tyrosine kinase inhibitor blocks EGF activation of EGFR/erbB2 and downstream Erk1/2 and AKT pathways
WL Xia et al.
ONCOGENE (2002)
The extracellular signal-regulated kinase pathway regulates the phosphorylation of 4E-BP1 at multiple sites
TP Herbert et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2002)
Familial chordoma, a tumor of notochordal remnants, is linked to chromosome 7q33
MJ Kelley et al.
AMERICAN JOURNAL OF HUMAN GENETICS (2001)
Platelet-derived growth factor requires epidermal growth factor receptor to activate p21-activated kinase family kinases
H He et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2001)
Does the tuberous sclerosis complex include clivus chordoma?: A case report
J Börgel et al.
EUROPEAN JOURNAL OF PEDIATRICS (2001)
Chordoma: incidence and survival patterns in the United States, 1973-1995
ML McMaster et al.
CANCER CAUSES & CONTROL (2001)
分享论文
